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Phe Effects of Phosphodiesterase-5 Inhibition
ith Sildenafil on Pulmonary Hemodynamics and
iffusion Capacity, Exercise Ventilatory Efficiency,
nd Oxygen Uptake Kinetics in Chronic Heart Failure
arco Guazzi, MD, PHD, FACC,* Gabriele Tumminello, MD,* Fabio Di Marco, MD,†
esare Fiorentini, MD,* Maurizio D. Guazzi, MD, PHD‡
ilan, Italy
OBJECTIVES We sought to investigate the effects of sildenafil, a phosphodiesterase-5 (PDE5) inhibitor, on
lung function and exercise performance in chronic heart failure (CHF).
BACKGROUND In CHF, nitric oxide-mediated regulation of lung vascular tone and alveolar-capillary
membrane conductance is impaired and contributes to exercise intolerance. The potential for
benefits due to increased nitric-oxide availability is unexplored.
METHODS In 16 patients with CHF and 8 normal subjects, we measured—before and 60 min after
sildenafil (50 mg) or placebo—ejection fraction, pulmonary hemodynamics, carbon monoxide
diffusion capacity (DLco), with its membrane (DM) and capillary blood volume (Vc)
subcomponents, endothelial function (brachial reactive hyperemia) at rest, peak oxygen
uptake (VO2), increments in VO2 versus work rate (VO2/WR), changes in ventilation
versus CO2 production (VE/VCO2) slope, and recovery VO2 time constant (tau) on exertion.
RESULTS In CHF, sildenafil did not affect cardiac index, wedge pulmonary pressure, or ejection
fraction; it significantly (p  0.01) decreased pulmonary mean artery pressure (20.4%) and
arteriolar resistance (45.1%), VE/VCO2 slope (9.0%) and recovery tau (25.8%), and
increased (p  0.01) DLco (11.1%), DM (9.9%) peak VO2 (19.7%), VO2/WR
(11.0%), and brachial reactive hyperemia (33.3%). No variations occurred in normal
subjects and after placebo. Changes in DLco were related to those in VE/VCO2 slope (r 
0.71; p  0.002), and changes in brachial hyperemia correlated with those in VO2/WR
(r  0.80; p  0.0002).
CONCLUSIONS This study shows that in CHF PDE5 inhibition modulates pulmonary pressure and vascular
tone, and improves DLco, exercise peak VO2, aerobic (VO2/WR) and ventilatory
(VE/VCO2 slope) efficiencies, and oxygen debt (recovery tau). Endothelial mechanisms may
underlie these effects. (J Am Coll Cardiol 2004;44:2339–48) © 2004 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.09.041College of Cardiology Foundation
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aitric oxide secretion by the pulmonary arterial and venous
ndothelia plays an important role in lung physiology (1)
ecause it is involved in the special capacity of the vascula-
ure to adapt to local changes in blood flow, in maintenance
f normal pulmonary vascular tone and permeability (2),
nd in the modulation of the tissue component of resistance
o O2 transfer from the alveolus to its uptake by hemoglobin
3).
At the lung level, chronic heart failure (CHF) is typically
ssociated with secondary hypertension, impaired vascular
eactivity and permeability, and reduced alveolar-capillary
embrane conductance (DM) (4). These factors contribute
o dyspnea sensation and exercise intolerance (5,6). The
uestion we have attempted to answer is whether a defective
itric oxide release disturbs the lung physiology in patients
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ilano, San Paolo Hospital, Milan, Italy; †Respiratory Unit, University of Milano,
an Paolo Hospital, Milan, Italy; and ‡Institute of Cardiology, University of Milano,
ilan, Italy. Supported, in part, by a grant from the Luigi Berlusconi Foundation,
ilano, Italy. Presented, in part, at the 76th American Heart Association Scientific
essions, Orlando, Florida, November 9 to 12, 2003.w
Manuscript received June 25, 2004; revised manuscript received August 27, 2004,
ccepted September 6, 2004.ith CHF, as it does in patients with primary pulmonary
ypertension (7), and whether a greater nitric oxide avail-
bility can be beneficial.
Sildenafil was used to investigate these issues because: 1) it is
selective inhibitor of cyclic 3=-5=-guanosine monophosphate-
pecific phosphodiesterase-5 (PDE5), the predominant isoen-
yme that metabolizes cyclic 3=-5=-guanosine monophosphate,
he second messenger of nitric oxide (8); 2) the gene encoding
DE5 is highly expressed in the lung (9); 3) PDE5 inhibitors
ave a promising therapeutic potential in pulmonary hyperten-
ion (10); 4) agonist-induced and shear stress-induced nitric
xide-mediated vasodilation are decreased in skeletal muscle
irculation of patients with CHF (11); and 5) acute PDE5
nhibition with sildenafil increases flow-mediated vasodilation
n CHF (12).
ETHODS
atients and normal subjects. The study includes 16 male
atients referred for evaluation of CHF and 8 healthy men
f similar age with atypical chest pain and normal coronary
ngiography and without any drug prescription. Patients
ere in stable clinical condition (New York Heart Associ-
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schemic or idiopathic cardiomyopathy. Eligibility criteria
ere: consent to participate in the study after information
oncerning procedures, risks, and possible clinical benefits;
eft ventricular ejection fraction 40%; forced expiratory
olume in 1 s (FEV1)/forced vital capacity (FVC) ratio
70%; and ability to complete a maximal exercise test.
atients were excluded if they had hypertension, pulmonary
isease, a pack-years index of cigarette smoking of more
han 10 (all had abstained from tobacco products for at least
months [13] before enrollment); if their carboxyhemoglo-
in was 2%; if exercise was limited by symptoms other
han dyspnea or fatigue and they developed electrocardio-
raphic changes of myocardial ischemia during exertion.
he anti-failure treatment was that prescribed by the
eferring physician and included diuretics (in all),
ngiotensin-converting enzyme inhibitors (14 patients),
eta-blockers (11 patients), and aspirin (10 patients). We
onsidered these patients as representative of the CHF
opulation. The experimental protocol was performed as
pproved by the local ethics committee. All subjects gave
ritten consent to the procedures, and none were excluded
fter study inclusion.
emodynamics. For cardiac output and pulmonary pres-
ure measurements, a 5-F thermodilution double-lumen
alloon-tipped catheter was inserted into an autecubital vein
nd positioned in the pulmonary artery. Systemic vascular
esistance (SVR) and pulmonary arteriolar resistance (PAR)
ere calculated as follows:
SVRMAPMRAP 1, 332 60 ⁄CO
PARMPPMWPP 1, 332 60 ⁄CO
here MAP  mean systemic arterial pressure, MRAP 
ean right atrial pressure, MPP mean pulmonary arterial
ressure, MWPP  mean pulmonary wedge pressure, and
O  cardiac output. Left ventricular dimensions and
Abbreviations and Acronyms
AT  anaerobic threshold
CHF  chronic heart failure
CPET  cardiopulmonary exercise testing
DLco  lung diffusing capacity for carbon
monoxide
DM  alveolar-capillary membrane
conductance
PDE5  phosphodiesterase-5
tau  oxygen uptake time constant
VA  alveolar volume
Vc  pulmonary capillary blood volume
VCO2  carbon dioxide output
VE/VCO2 slope  slope of increase in ventilation versus
carbon dioxide output
VO2  oxygen uptake
VO2/WR  rate of oxygen uptake increase per
work rateolumes and mitral regurgitation were quantitated withwo-dimensional and Doppler echocardiography. These
easurements were obtained at rest.
ulmonary function tests. Spirometry was performed with
quipment that met the American Thoracic Society perfor-
ance criteria (13). To adjust for height, age, and gender we
sed prediction equations for FEV1 and FVC (14).
Diffusing lung capacity for carbon monoxide (DLco) was
etermined twice with washout intervals of at least 4 min
the average was taken as the final result) with a standard
ingle breath technique. A test gas was used with 0.28%
arbon monoxide, 0.30% methane, 21% oxygen (O2), and
he balance made up of nitrogen. The DM and the capillary
ulmonary blood volume available for gas exchange (Vc)
ere determined with the classic method of Roughton and
orster (15). The single-breath alveolar volume (VA) was
erived by methane dilution.
ardiopulmonary exercise testing (CPET). Subjects per-
ormed a standard, progressively increasing (personalized
amp protocol) work rate (WR) CPET to maximum toler-
nce on a cycle ergometer in the upright position. Gas
xchange measurements (Cardiopulmonary Metabolic Cart,
ensormedics Vmax Spectra, Sensormedics, Yorba Lima,
alifornia) were obtained at rest (2 min) and during 2 min
f unloaded leg cycling at 60 rpm, followed by a progres-
ively increasing WR exercise. Heart rate, 12-lead electro-
ardiogram, and cuff blood pressure were monitored and
ecorded.
able 1. Baseline Characteristics of Study Subjects
Normal
Subjects Patients
umber 8 16
ender (M/F) 8/0 16/0
ge (yrs) 57.6  7.2 55.1 8.2
eight (kg) 76.3 5.4 74.7 6.6
ody mass index 26  3 25  2
tiology of heart failure (IHD/DCM) — 11/5
itral regurgitation (subjective scale, 0–4) — 1.3  0.7
orced vital capacity (% predicted) 96.3  10.1 91.6 7.8
orced expiratory volume in 1 s
(% predicted)
97.6  11.0 87.8 8.7*
Lco (% predicted) 99.2  7.1 75.9 9.9*
Lco/VA (% predicted) 97.8  8.3 75.4 12.6*
ardiac index (l·min1·m2) 3.127  112 2.234  127*
eft ventricular ejection fraction (%) 68.2  5.4 30.2 3.2*
ystemic arterial pressure (mm Hg)
Systolic 128.5 5.2 121.1  6.8
Diastolic 79.6  2.3 74.8 1.5
ulmonary arterial pressure (mm Hg)
Systolic 23.5 4.2 33.6 3.3*
Diastolic 12.8  3.7 21.5 2.7*
Wedge 11.9  2.8 18.9 3.1*
ystemic vascular resistance
(dynes·s·cm5)
1,236  188 1,938  136*
ulmonary arteriolar resistance
(dynes·s·cm5)
76  17 129 18*
p  0.01 vs. normal subjects.
DCM  idiopathic dilated cardiomyopathy; DLco  lung diffusing capacity for
arbon monoxide; IHD  ischemic heart disease; VA  alveolar volume.Minute ventilation (VE), oxygen uptake (VO2), carbon
Table 2. Hemodynamic Values at Baseline and After Sildenafil (50 mg) or Placebo Intake in Normal Subjects and in Patients with CHF (means  SD)
Normal Subjects CHF Patients
Baseline Placebo  Baseline Sildenafil  Baseline Placebo  Baseline Sildenafil 
Subjects (n) 8 8 8 8 16 16 16 16
Heart rate (beats/min) 66.1 2.7 67.8 2.8 1.7 66.5  2.6 68.0 2.6 1.5 72.3  2.8 71.9 2.7 0.4 71.4  2.4 71.0  7.7 0.4
Systemic arterial pressure
(mm Hg)
Systolic 125.4 4.2 126.5 3.8 1.1 127.2  4.2 125.7 5.2 1.5 120.3  6.7 121.0 6.8 0.7 121.4  6.4 115.6  9.0 5.8
Diastolic 77.5 3.8 79.4 2.6 1.9 78.3  2.3 78.2 3.1 0.1 74.7  2.8 74.6 5.7 0.1 75.3  3.2 73.7  5.6 1.6
Cardiac index (l·min1·m2) 3.247  131 3.180 13.0 0.067 3.209  118 3.259 129 0.050 2.271  132 2.231 138 0.040 2.211  130 2.345  138 0.134
Systemic vascular resistance
(dynes·s·cm5)
1,210  166 1,256 162 46 1,225  162 1,200 152 25 1,935  149 1,950 135 15 1,895  149 1,805  153 90
Left ventricular ejection
fraction (%)
66.7  3.3 67.7 3.4 1 67.3  4.3 66.2 4.0 1.1 30.2  3.1 31.6 2.8 1.4 30.8  3.0 32.9  2.6 2.1
Pulmonary arterial pressure
(mm Hg)
Systolic 24.0 3.7 24.1 3.9 0.1 23.5  4.1 23.7 4.0 0.2 33.7  3.2 33.5 2.9 0.2 32.9  2.7 25.7  3.1*† 7.2†
Diastolic 12.6 3.1 12.3 3.5 0.3 12.6  3.2 12.1 3.9 0.5 22.2  2.5 22.1 2.7 0.1 22.2  2.6 17.6  2.7*† 4.6†
Wedge pulmonary pressure
(mm Hg)
11.1  2.2 10.7 2.5 0.4 10.7  3.3 10.2 3.6 0.5 19.4  2.7 19.6 2.3 0.2 18.5  3.0 17.3  2.7 1.2
Pulmonary arteriolar resistance
(dynes·s·cm5)
71  26 75  29 4.0 74  20 76  23 2.0 129  16 131 16 2.0 127  17 57  15*† 70†
*p  0.01 vs. baseline; †p  0.01 vs. placebo.
CHF  chronic heart failure.   changes from baseline.
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Sildenafil and Exercise Capacity in Heart Failure December 21, 2004:2339–48ioxide output (VCO2), and other exercise variables were
omputer-calculated breath-by-breath, interpolated second-
y-second, and averaged at 10-s intervals. The V-slope
nalysis method was used to measure the anaerobic thresh-
ld (AT).
The VO2 at the AT and the rate at which VO2 increased
er work rate (VO2/WR), as an indicator of aerobic
fficiency, were also assessed. The VO2/WR was calcu-
ated using all VO2 data for the progressively increasing
xercise period beginning 1 min after WR started to
ncrease until peak exercise. According to what has recently
een proposed by Mitchell et al. (16), we measured the VO2
inetics during exercise using the last minute of unloaded
edaling (to determine delay of increase in VO2 before and
ith the start of exercise) and the VO2/WR alone that
as measured by linear regression analysis, taking into
ccount the inflection point at AT. We also recorded the
inetics for the first 6 min after peak exercise to allow for
etermination of recovery time constant for VO2 (tau). Tau
alculation was performed by fitting the VO2 data to a
onoesponential curve VO2  AeBTD	  C.
Peak VO2 was the highest VO2 achieved during exercise.
he O2 arterial saturation was monitored with an ear
xymeter (Sensormedics).
ascular studies. Imaging studies of the brachial artery
ere performed with a high-resolution ultrasound
ewlett-Packard 11 MHz linear-array transducer (Palo
lto, California). Brachial flow velocity was assessed by
ulsed Doppler with the range gate (1.5 mm) in the
enter of the artery. The system permitted an evaluation
f the angle between blood stream and the intersecting
ltrasound beam, which was used to calculate blood flow
elocity. Images were obtained by the same investigator
hroughout the study. Flow-mediated vasodilation was
easured as change in brachial artery diameter during
yperemia after release of a cuff inflated (50 mm Hg
bove systolic pressure for 5 min) on the forearm.
iameter was measured in millimeters, coincident with
he R waves on the electrocardiogram, at two sites along
he artery for three cardiac cycles, with these six mea-
urements averaged. Images and vasodilating responses
rom repeated studies were analyzed by an investigator
lind to the sequence.
We calculated blood flow, multiplying the velocity-time
ntegral of the Doppler flow signal by the vessel cross-
ectional area and heart rate. The flow-mediated dilation
as calculated as absolute maximal change in diameter (30
after cuff deflation) compared with baseline. Reactive
yperemia was calculated as absolute maximal change in
ow during hyperemia compared with baseline.
Sources of variability were studied for measurement of
rachial artery diameter (BAD) and flow-mediated dila-
ion (FMD) in the control condition (C) and after
ildenafil (S). For reproducibility, coefficients of varia-
ions were: BADC  2.3, BADS  2.5, FMDC  3.1,
MDS  2.8. For repeatability, coefficients of variation sere: BADC  2.7, BADS  2.5, FMDC  2.9, FMDS
3.0.
rotocol. Subjects were hospital admitted. Patients were
aintained on their current drug therapy, and control
ubjects did not receive any cardiovascular treatment. After
outine laboratory work and cardiac evaluation, they per-
ormed a graded CPET to determine peak VO2. Then
ubjects underwent pulmonary evaluation, including diffu-
ion capacity, and these measurements were taken as base-
ine parameters, as far as the lung function is concerned
day 1). On the following day (day 2), drug studies were
erformed in all participants after a 12-h overnight fast in a
uiet room. Patients’ morning doses of their usual medica-
ions were withheld. A second CPET was performed, and
esults were taken as baseline measurements. A 5-F ther-
odilution balloon-tipped catheter was floated to the pul-
onary circulation. After a 30-min rest, diameter and flow
f the brachial artery were measured before cuff inflation. A
econd scan was taken for 90 s after cuff deflation with
easurements taken 15, 30, 60, and 90 s after deflation.
fter an additional 30-min rest, baseline blood pressure
cuff method), right atrial pressure (proximal port of the
atheter), pulmonary arterial and wedge pressures, and
ardiac output (average of three determinations) were eval-
ated. Then 50 mg of sildenafil or placebo were adminis-
ered orally. The criteria for selection of a 50-mg dose was
hat of utilizing the minimal dose that, in a pilot assay in five
imilar patients, significantly reduced the pulmonary arte-
iolar resistance.
Sixty minutes later (to coincide with the expected peak
lasma concentration after oral dosing [8]), hemodynamics,
ulmonary function, and brachial flow-mediated vasodila-
ion were reevaluated in that order, at rest. Then, according
o the indications of the ethics committee, the catheter was
ithdrawn and a CPET was repeated. Measurements were
ot made at other times after dosing in order to allow at
east 24-h before reassessing DLco and its subcomponents.
n the following morning (day 3), we repeated the same
rocedures as on day 2, while patients were switched to
lacebo or sildenafil according to a random double-blind
rossover design.
tatistical analysis. Randomization was performed ac-
ording to a randomization list generated by computer.
alues are expressed as the mean values  SD. Repeated
easures analysis of variance test and Newman-Keuls mul-
iple comparison procedure were used to compare measure-
ents after placebo and after sildenafil intake. The incre-
ental changes from baseline with active drug compared
ith placebo were analyzed with a paired t test.
Differences between control subjects and patients were
nalyzed by an unpaired t test. The relationships of changes
n DLco versus those in VE/VCO2 slope and changes in
rachial reactive hyperemia versus those in VO2/WR, as
ell as those between tau recovery versus brachial reactive
yperemia and VO2/WR, were assessed using the Pear-
on coefficient of correlation. A p value of 0.05 was
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y means of the Stata 7.0 package (Stata Corp. LP, College
tation, Texas).
ESULTS
one of the patients or normal subjects was withdrawn for
ajor adverse events. The two populations were similar as
o gender, age, and body mass index (Table 1). In patients,
Lco and DLco/VA were reduced to 75.9% and 75.4% of
redicted normal values, respectively; FEV1 and FVC were
7.8% and 91.6% (Table 1). Compared with healthy sub-
ects, left ventricular ejection fraction and cardiac index were
educed; systolic, diastolic, and wedge pulmonary pressures
nd pulmonary arteriolar resistance were elevated (Tables 1
nd 2). As to the CPET parameters (Table 3), patients
xhibited significant lower peak VO2, VO2 at AT, and
igher dead-space-to-tidal-volume ratio (VD/VT) and VE/
CO2 slope. No significant differences in VO2 time delay
ere observed. The VO2/WR, which reflects the O2
tilized per unit increase in WR and is an index of aerobic
fficiency, averaged 8.0  1.9 ml·W1·min1, compared
ith 10.6  3.0 ml·W1·min1 in normal controls. The
ecovery tau in patients (76.7  14.0 s) exceeded that in
ealthy subjects by 42% (44.0  16.0 s).
Flow-mediated changes in brachial artery diameter and
eactive hyperemia were significantly smaller in patients
han in normal individuals (Table 4).
Variations from baseline (with placebo or sildenafil) in
emodynamic, CPET, brachial artery, and pulmonary func-
ion data are reported in Tables 2 to 5, respectively. Because
here was no time or order effect, data are presented
egardless of the order in which placebo and sildenafil were
iven. In healthy subjects, after a 60-min interval following
lacebo or sildenafil, the hemodynamic, CPET, respiratory,
nd vascular variables all were similar to those detected at
aseline. No significant variations with placebo were ob-
erved in patients with CHF. On the contrary, measure-
ents performed after sildenafil in this group showed a
eduction in pulmonary systolic (21.8%) and diastolic
20.7%) arterial pressures and arteriolar resistance
45.1%), without significant changes in cardiac index
6.0%) and wedge pulmonary pressure (6.4%) (Table 2).
here was an increase in DLco (11.1%) and DM (9.9%)
Table 5). Sildenafil improved DLco and DM in all but one
atient. These variations, when expressed per unit VA, were:
Lco/VA 20%, DM/VA 19%. Arterial O2 saturation in
ither population was normal both at baseline and during
eak exercise, and did not vary after sildenafil (Table 5). The
orearm reactive hyperemia and flow-mediated dilation were
ignificantly augmented after PDE5 inhibition (Table 4).
As shown in Table 3, sildenafil was associated with signif-
cant decrease in VD/VT (13.6%) and VE/VCO2 slope
9.0%), and increase of exercise workload at AT (14.1%)
nd at peak exercise (11.0%), peak VO2 (19.7%), VO2 at
T (20.6%), and VO2/WR (11.0%). The VO2/ T
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Table 4. Brachial Artery Data at Baseline and After Placebo or Sildenafil Intake in Normal Subjects and in Patients With CHF (Mean  SD)
Normal Subjects CHF Patients
Baseline Placebo  Baseline Sildenafil  Baseline Placebo  Baseline Sildenafil 
Subjects (n) 8 8 8 8 16 16 16 16
Flow-mediated changes in diameter
(mm)
0.43  0.04 0.44  0.03 0.01 0.43  0.02 0.43  0.04 0 0.25  0.02 0.26  0.03 0.01 0.28  0.03 0.36  0.02*† 0.08†
Reactive hyperemia (ml·min1) 430  35 432  42 2.0 428  34 439  38 11.0 258  47 253  51 5.0 261  50 348  61*† 87†
 diameter/ flow
(mm·ml1·min1·1,000)
0.99  0.07 0.98  0.06 0.01 1.01  0.08 0.97  0.06 0.04 0.87  0.09 0.89  0.07 0.02 0.87  0.13 1.04  0.07*† 0.17†
*p  0.01 vs. baseline; †p  0.01 vs. placebo.
CHF  chronic heart failure;   differences from baseline.
Table 5. Pulmonary Function Data at Baseline and After Placebo or Sildenafil Intake in Normal Subjects and Patients with CHF (Mean  SD)
Normal Subjects CHF Patients
Baseline Placebo  Sildenafil  Baseline Placebo  Sildenafil 
Subjects (n) 8 8 8 16 16 16
DLco (ml·min1·mm Hg1) 28.8  3.9 27.2 3.9 1.6 27.9  4.7 0.9 21.5  4.0 21.3 3.6 0.2 23.9  4.0*† 2.4†
DLco/VA (ml·min
1·mm Hg1) 5.5  0.9 5.2  0.7 0.3 5.3  0.8 0.2 3.9  0.6 3.8 0.6 0.1 4.7  0.5*† 0.8†
DM (ml·min
1·mm Hg1) 44.7  2.8 45.1 3.4 0.4 44.3  4.1 0.4 30.3  6.3 30.0 4.9 0.3 33.3  5.0*† 3.0†
DM/VA (ml·min
1·mm Hg1) 8.6  1.7 8.5  2.1 0.1 8.4  1.3 0.2 5.6  1.2 5.5 1.0 0.1 6.7  0.9*† 1.1†
DLco/DM (ml·min
1·mm Hg1) 64.4  5.3 60.3 4.8 3.1 62.8  5.6 1.6 70.2  6.1 70.0 5.0 0.2 71.4  5.3 1.2
Arterial oxygen saturation (%) 98.3  0.5 98.1 0.4 0.2 98.0  0.5 0.3 97.7  0.7 97.9 0.4 0.2 98.1  0.7 0.4
*p  0.01 vs. baseline; †p  0.01 vs. placebo.
CHF  chronic heart failure; DLco  lung diffusion for carbon monoxide; DM  alveolar-capillary membrane conductance; VA  alveolar volume;   changes from baseline.
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nd above the AT from 8.4  2.0 to 10.6  1.9 (p  0.01),
uggesting that an efficiency improvement occurred both below
nd above the AT. A consistent improvement in VO2 kinetics
as observed, as documented by a significant reduction in
ecovery tau from 76.7  14.1 s to 56.9  12.8 s. A
epresentative case describing CPET changes during placebo
nd after sildenafil intake is reported in Figure 1. Peak VO2
ncreased in 14 of 16 patients, and the VE/VCO2 slope
ecreased in all patients.
The reduction from baseline in VE/VCO2 slope with
ildenafil was related to the increase in DLco (r0.71; p
.0021), and changes in VO2/WR were related to those in
rachial reactive hyperemia (r 0.80; p 0.0002) (Fig. 2). A
ignificant inverse relationship was found, both in the baseline
nd after sildenafil, of recovery tau with VO2/WR and with
rachial reactive hyperemia (Fig. 3). There was no relationship
etween VE/VCO2 slope and DLco at baseline or between
rachial hyperemia and VO2/WR at baseline, as well as
etween age, etiology, and duration of heart failure and drug
herapy, with changes in pulmonary artery pressure, arteriolar
esistance, DLco, and DM.
These effects were not detectable 24 h later at measure-
igure 1. Cardiopulmonary exercising testing measurements (A, oxygen u
roduction [VE/VCO2 slope]; and C, rate of oxygen uptake increase per w
econdary to ischemic cardiomyopathy (age 60 years, left ventricular ejectio
lacebo and after sildenafil intake. Protocol consisted of 2 min of rest, 2 mi
o maximal exercise tolerance, and 6 min of recovery. Oxygen uptake kinetic
econd-by-second, and averaged at 10-s intervals; VE/VCO2 incremental c
ncremental changes during maximal exercise data are plotted at 20-s inteents performed in patients who were given placebo as uecond test drug. There were no major adverse effects
ttributable to the research procedures or to sildenafil.
inor adverse reactions to sildenafil administration con-
isted of flushing in three patients and in one healthy
ubject.
ISCUSSION
he novel findings are that, in CHF, PDE5 inhibition
ttenuated secondary pulmonary hypertension by lowering
rteriolar resistance, facilitated alveolar gas exchange, and
mproved overall exercise performance, VO2 kinetics (recov-
ry tau), and ventilation efficiency. In addition, sildenafil
ignificantly improved the brachial artery flow-mediated
ndothelial function. These effects were not observed in
ontrol subjects.
emodynamics and alveolar gas diffusion. A previous
tudy has prospected the possibility that sildenafil increases
he ventricular contractile function (17). This, however,
oes not seem an appropriate explanation for changes
bserved in the pulmonary hemodynamics. In fact, as
eported in other studies (18), wedge pulmonary pressure,
ardiac output, and left ventricular ejection fraction were
[VO2] kinetics; B, slope of increase in ventilation versus carbon dioxide
ate [VO2/WR]) of one patient with moderate congestive heart failure
tion of 34%, and systolic pulmonary pressure of 38 mm Hg) recorded after
nloaded exercise at 60 rpm (Unl. Exe. ), ramp work rate of 15 W · min1
were computer-collected as breath-by-breath measurements, interpolated
es during maximal exercise data are plotted at 20-s intervals; VO2/WRptake
ork r
n frac
n of u
s datanchanged after sildenafil.
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ension in CHF are not entirely understood (19). Notably,
n the present study, PDE5 inhibition lowered arteriolar
esistance in a vascular bed in which endothelium nitric
xide synthase is highly expressed (7) and in a clinical
etting, heart failure, in which nitric oxide-mediated vaso-
ilation is basically impaired (11). The interpretation that
DE5 blockade lowers the pulmonary arteriolar resistance
igure 2. Correlations of changes, after sildenafil, in lung diffusing capac
hanges in slope of increase in ventilation versus carbon dioxide output (VE
n patients with chronic heart failure.igure 3. Correlations of changes in rate of oxygen uptake increase per work ra
au recovery, at baseline and after sildenafil, in patients with chronic heart failund pressure in patients with CHF by enhancing nitric
xide availability is consonant with these findings, as well as
ith the view that a defective nitric oxide release is typical
f the syndrome and facilitates pulmonary vasoconstriction
19).
In anesthetized pigs, sildenafil administration augmented
ntrapulmonary shunt flow and lowered arterial O2 satura-
ion (17). These responses have been attributed to a vaso-
r carbon monoxide (DLco) versus brachial artery reactive hyperemia and
2 slope) versus rate of oxygen uptake increase per work rate (VO2/WR)ity fo
/VCOte (VO2/WR) versus tau recovery and brachial artery hyperemia versus
re.
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December 21, 2004:2339–48 Sildenafil and Exercise Capacity in Heart Failureilating effect and to a substantial increase in cardiac output
hat, in the presence of an unchanged ventilation, may have
aused an inadequate gas exchange (17). Because of this,
ildenafil effects on pulmonary hemodynamics and gas
xchange might be undesired in patients with obstructive
ulmonary disease (low ventilation/perfusion ratio) or with
oronary disease (decrease in O2 tension combined with an
ncrease in cardiac output) (17). Our results are not consis-
ent with increase in lung perfusion or with the occurrence
f some arterial O2 desaturation in normal subjects (18), as
ell as in patients with CHF when current doses of
ildenafil are used. These drawbacks, therefore, would not
reclude a possible use of the drug in patients with CHF.
Remarkably, PDE5 inhibition promoted a very favorable
eduction of the alveolar-capillary membrane resistance to
as exchange (improvement in DM despite no changes in
c). In CHF, elevation of hydrostatic forces, enhancement
f sodium transport across the capillary endothelium, and
eduction in active fluid reabsorption by alveolar epithelium
20,21) may concur to facilitate alveolar interstitial fluid
ccumulation and to limit gas exchange. Under this respect,
pertinent question is whether an improved DLco was
elated to the diminished pulmonary vascular tone, or to a
irect effect mediated by the augmented nitric oxide avail-
bility, or both. How much of the benefit of sildenafil on gas
ransfer is due to a decrease of pulmonary vascular tone and
ressure cannot be estimated. However, some consider-
tions are in order. DLco increased because of a better
lveolar membrane conductance, instead of an increased
ulmonary capillary volume available for gas exchange (as
ould be expected if vasodilation were to be the mecha-
ism). Hydralazine and nitrates (22) fail to improve DLco,
espite a substantial pulmonary vasodilating activity. Insu-
in, on the contrary, in the absence of lung vasodilation (3),
ignificantly improves conductance of the alveolar-capillary
embrane, as well as exercise ventilatory efficiency, in
atients with diabetes (23). Activation by insulin of the
efective release of substances, such as endothelium-derived
itric oxide, has been offered as an explanation of these
ffects, because nitric oxide, like vasodilating prostaglandins
2,3), modulates the pulmonary vascular permeability and
an reduce the tissue component of resistance to the O2
ransfer from the alveolus to its uptake by hemoglobin.
hese considerations may apply to sildenafil, mainly taking
nto account that lung function amelioration was paralleled
y a substantial enhancement in the brachial artery endo-
helial function, and that a combination of a vascular and
ung effect similar to this is also observed in CHF patients
ith exercise training (24), an efficacious stimulus for the
elease of endothelial paracrine agents. Thus, we propose
he explanation of a greater nitric oxide availability as a
echanism for pulmonary vascular tone reduction and
acilitation of gas diffusion after PDE5 inhibition.
xercise ventilation efficiency and VO2 kinetics. Patients
ith CHF peculiarly exhibit an abnormal ventilatory re-
ponse to exercise, characterized by a steep VE/VCO2 slope. fhe increase in VE/VCO2 slope may be multifactorial:
ncrease of the ventilation required to overcome a large dead
pace, augmented central drive to ventilation originating
rom J-receptor activation in consequence of the interstitial
pace distension, bicarbonate buffering of accumulating
actic acid, reduced perfusion of ventilating lung, abnormal
hemosensitivity, overactive ergoreceptors, abnormal auto-
omic and baroreceptor control of the circulation (25). In
ddition, in the presence of left ventricular dysfunction,
xercise abnormally raises the pulmonary capillary pressure
nd the fluid flux transition. Thus, gas conductance may
orsen because of an excessive fluid accumulation in the
lveolar interstitium. Hyperventilation might help maintain
2 alveolar tension at normal levels, at the price, however,
f premature exhaustion of the ventilatory reserve and early
xercise interruption. This study does not define the respec-
ive roles of these factors; however, the improvement in DM,
s possibly mediated by reduction of lung interstitial space
verdistension and its correlation with the increased venti-
atory efficiency (i.e., reduced VE/VCO2 slope steepness),
re in favor of an involvement of the membrane effects of
DE5 inhibition. Likewise, the reduction of pulmonary
ead space during exercise (decreased peak VD/VT) and the
ncrease in VO2/WR (potentiated aerobic efficiency both
elow and above AT) are consistent with an influence of
DE5 inhibition on more than one mechanism underlying
he VE/VCO2 slope improvement.
A better exercising muscle perfusion may also well explain
he benefits of sildenafil on VO2 AT, peak WR, and peak
O2 (26). Nitric oxide has a physiologic role to dilate
keletal muscle vasculature, and this activity is impaired in
everal disorders including heart failure (9). The increase in
VO2/WR reflects an increased quantity of O2 utilized
er unit increase in work rate and is a measure of aerobic
fficiency. An improved O2 diffusion from the capillaries to
itochondria or a facilitation of exercising muscle perfusion
changes in VO2/WR significantly correlated with vari-
tions in brachial artery reactive hyperemia with sildenafil)
re factors potentially involved in the raised VO2/WR.
n our population, peak respiratory exchange ratio averaged
.18 at baseline, and no changes were observed after
ildenafil, suggesting a similar energetic substrate utiliza-
ion. Consonant with these interpretations is the reduction
n the recovery tau implying that O2 debt accumulation,
hich is repaid after exercise, is mitigated by PDE5 inhi-
ition. Better correlations of recovery tau with VO2/WR
nd brachial artery dilation were observed after sildenafil
ntake.
These considerations, altogether, support the possibility
hat, in patients with CHF, impaired gas exchange effi-
iency is involved in the reduced peak VO2, and that PDE5
nhibition increases peak VO2 and reduces exercise O2 debt
hrough a synergistic activity on central (lung) and periph-
ral (exercising muscle vasomotility) mechanisms.
onclusions. In conclusion, this study provides novel in-
ormation concerning the pathophysiology of CHF and the
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ossesses the potential for future investigative and therapeu-
ic developments.
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